Company profile
Acumen Pharmaceuticals company profile
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://www.acumenpharm.com
- Contact email
- [email protected]
- Phone number
- +1 6508757772
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $1K+
- Founded
- 1996-01-01
Headquarters
- Headquarters
- Parker, Florida, United States
- Postal code
- 46032
- Country code
- US
- Continent
- North America